What is Drik?
Drik operates as a sophisticated contract research organization (CRO) focused on the critical intersection of preclinical drug development and rigorous safety assessment. By leveraging advanced methodologies such as 3D Organotypic slice cultures, the company provides essential data that mitigates risk for pharmaceutical, cosmetic, and chemical entities. Their market position is defined by a commitment to high-quality toxicology assessments, offering a comprehensive suite of services that range from in vitro testing to complex animal studies. As regulatory scrutiny intensifies globally, Drik serves as a vital partner for innovators seeking to validate the safety profiles of their future discoveries before clinical entry.
How much funding has Drik raised?
Drik has raised a total of $27K across 1 funding round:
Debt
$27K
Debt (2021): $27K with participation from PPP
Key Investors in Drik
PPP
Public-Private Partnership
What's next for Drik?
With the recent infusion of substantial expansion capital, Drik is strategically positioned to scale its laboratory infrastructure and broaden its service portfolio. The company is expected to prioritize the enhancement of its proprietary assay development, ensuring that it remains at the forefront of toxicological research. By scaling its operational capacity, Drik aims to capture a larger share of the outsourced research market, effectively supporting the accelerated development timelines of its global client base. Future growth will likely hinge on the firm's ability to integrate emerging biotechnological trends into its existing safety testing frameworks, thereby solidifying its reputation as a leader in preclinical research excellence.
See full Drik company page
